INTRODUCTION
Vitamin K is an essential cofactor for the production in the liver of biologically active forms of the coagulation factors II (prothrombin), VII, IX, and X. Its role is to promote the conversion of certain glutamic acid residues in the protein precursors to γ-carboxyglutamic acid (Gla). The Gla-residues of these coagulation factors provide an efficient chelating site for calcium ions and are essential for protein-membrane interaction and effective haemostatic function 11 . When γ-carboxylation is impaired because of deficiency or antagonism of vitamin K, inert precursors of vitamin Kdependent proteins  known as Proteins Induced by Vitamin K Absence or Antagonism (PIVKA)  are synthesised in the liver and released into the blood 2, 32, 3 .
In the case of prothrombin, specific and sensitive immunoaassays have been developed which can detect small decreases in the Gla content of prothrombin before any changes occur in conventional coagulation tests such as the International Normalised Ratio (INR) 3-63-6 .
The major dietary form of vitamin K is phylloquinone (vitamin K 1 ; K 1 ), which is derived predominantly from green leafy vegetables. Its intestinal absorption involves the intraluminal solubilisation of vitamin K into mixed micelles composed of bile salts and the products of pancreatic lipolysis. This absorption is known to be impaired in patients with extrahepatic biliary obstruction and severe pancreatic insufficiency 77 , but there are no data in patients with liver disease. Although impaired hepatic synthesis is almost certainly the dominant factor in the development of the usually severe coagulopathy seen in patients with acute liver failure (ALF), such patients may also have multiple risk factors for vitamin K deficiency, including poor oral intake, severe cholestasis and treatment with broad spectrum antibiotics  which inhibit production of menaquinones (vitamin K 2 ) by certain intestinal bacteria and their subsequent ileal absorption 88 . Consequently, it has been recommended that intravenous (i.v.) K 1 be given empirically to exclude a contribution of vitamin K deficiency to the coagulopathy 99 .
A commonly prescribed formulation of K 1 is Konakion ® MM (F. Hoffmann-La Roche Ltd, Basle, Switzerland), which contains phylloquinone solubilised in glycocholatephosphatidylcholine mixed micelles. We have shown that the mixed-micellar K 1 (MM K 1 ) formulation is associated with a lower risk of anaphylactoid reactions after i.v. administration than the original Konakion, which contained the nonionic detergent Cremophor EL ® as solubiliser 10 , but that 10 the intestinal absorption of MM K 1 in infants with conjugated hyperbilirubinaemia, given as prophylaxis against vitamin K deficiency bleeding of the newborn, is unreliable 1112 . There is no information on the efficiency of intestinal absorption of MM K 1 in adults with liver disease.
The aims of this randomised, double-blind, placebo-controlled study were to: (i) assess the possible contribution of vitamin K deficiency to the coagulation disorder found in patients with severe acute liver damage, and (ii) compare the pharmacokinetics and efficacy of oral versus i.v. MM K 1 in correcting any underlying vitamin K deficiency.
PATIENTS AND METHODS
Over an eight-month period, 49 patients (24 women, 25 men; mean age 34 years, range 16-73 years) with, or at high risk of developing, ALF 1213 , were transferred to the Liver Failure Unit of King's College Hospital and enrolled into the study by one of two investigators (SPP and DR). As part of the eligibility criteria, all of the patients had an INR > 2 at admission, and none had received K 1 within the preceding three days. The commonest cause of acute liver dysfunction was acetaminophen paracetamol hepatotoxicity (n=37; 76%), followed by other drugs (ecstasy in four, paroxetine in one) in 10%. The final diagnoses in the remainder were presumed nonA-E viral hepatitishepatitis of unknown origin in two, malignant hepatic liver infiltration in two, and one case each of acute fatty liver of pregnancy and Amanita phalloides poisoning.
At admission, 27 patients (55%) had already developed ALF and were encephalopathic and/or mechanically ventilated, and eight (16%) had a marked metabolic acidosis (arterial pH <7. 
Assessment of vitamin K status
Vitamin K status was assessed from serum measurements of K 1 and by a sensitive functional assay based on the detection of undercarboxylated species of prothrombin (PIVKA-II).
Blood samples were collected before administration of the study medications (baseline sample) and on the three consecutive mornings after admission, with further samples on days five and seven unless the patient had died or been discharged. At each sampling time, 10 ml of venous blood was collected into plain tubes, protected from light and allowed to clot at 4°C. Serum was separated by centrifugation and stored at -70°C.
Serum vitamin K 1 assay: Serum K 1 was measured by high performance liquid chromatography (HPLC) with electrochemical detection in the redox mode, as described previously 1415 . Volumes of 0.05 ml serum were first analysed by a protocol designed to measure K 1 concentrations in the pharmacological range (>5 ng/ml) 1415 .
If the level was <10 ng/ml by this protocol, volumes of 0.2-0.5 ml serum were subjected to a protocol for endogenous concentrations 1415 . Menaquinone-6 was used as the internal standard. For 0.5 ml serum extracted, the lower limit of detection was 0.05 ng/ml. The mean intra-and inter-assay precision values (RSD %) were 3% and 9%, respectively, for concentrations in the pharmacological range, and 5% and 10% for endogenous concentrations. The normal adult reference range by the same assay was 0.17-0.68 ng/ml (median 0.37 ng/ml) in the fasting state, and 0.15-1.55 ng/ml (median 0.53 ng/ml) in non-fasting subjects 1516 .
Serum PIVKA-II assay: Serum PIVKA-II was assayed using a conformation-specific monoclonal antibody (which does not cross-react with fully carboxylated native prothrombin) in a modification of a previously described ELISA-based assay 55 . Serum PIVKA-II by immunoassay is conventionally expressed as Arbitrary Units per ml (AU/ml) since, in states of vitamin K deficiency, circulating PIVKA-II may comprise multiple forms of partially carboxylated prothrombin and neither their relative abundance in plasma nor their relative affinity for the antibody is known.
Calibration is therefore made against PIVKA-II species purified from patients treated with oral anticoagulants. Using electrophoretic techniques, 1 AU is equivalent to 1 µg of purified PIVKA-II 55 . The minimum limit of detection for our assay was 0.15 AU/ml. In 43 adult patients on warfarin therapy (INR > 1.5), the mean value in our laboratory was 40.0 AU/ml (range 6.9-99.5 AU/ml) 1617 . As previously reported 1718 , there was good agreement between the specificity of this assay and a commercial kit (Eitest mono-II; Eisai Co Ltd, Tokyo) which has been used widely for the detection of subclinical vitamin K deficiency 18-2019-21 .
Statistical analysis
Data are expressed as means ± SEM. Group means were compared using the the Student's t test (two-tailed), and differences in proportions were assessed using the χ 2 test. Pearson's correlation coefficients were calculated to assess the strength of relations between the serum K 1 terminal half-lives (determined by log-linear regression analysis of the 24 h and 48 h data) and the severity of liver and renal dysfunction.
Written, informed consent was obtained from the patients or their next-of-kin. The study was approved by the Research Ethics Committee of King's College Hospital.
RESULTS
The clinical details and laboratory values at admission of the three study groups are given in Table 1 . The three groups were well-matched for sex, aetiology and severity of liver dysfunction, although patients in the oral group were somewhat younger than those in the other two groups (27 v 37 yr; p=0.03). The mean INR at admission was Twenty-seven of the 49 patients (55%) made a full recovery with intensive care support, and eight others (16%) who fulfilled the King's criteria for transplantation in ALF 1213 were transplanted on day 3-30 (median six) and later discharged. Fourteen other patients (29%) died 3-10 days (median six) after admission, generally due to chest sepsis with multiorgan failure or cerebral oedema. Ten patients in this group fulfilled transplant criteria, but either had medical or psychiatric contraindications to transplantation (n=7) or died before transplantation could be carried out (n=3). 
Serum vitamin K 1
Mean baseline serum concentrations of K 1 were similar in the three groups, being 1.6 ±0.4 ng/ml (range, 0.2-6.5 ng/ml) in the i.v. MM K 1 group, 2.4±0.8 ng/ml (0.1-10.0 ng/ml) in those given MM K 1 orally, and 2.2±0.08 ng/ml (0.03-6.5 ng/ml) in the placebo group (NS). Three of the 49 patients (6%) had pretreatment serum K 1 levels below the normal limit of 0.15 ng/ml (one in the oral group and two in the placebo group), and a further two patients (both in the placebo group) developed low levels within 48 h after admission despite clinical improvement in both patients. In those given placebo, there was a progressive fall in mean serum K 1 concentrations with time, from 2.2±0.08 ng/ml (0.03-6.5 ng/ml) at admission, to 1.8 ng/ml (0.1-4.5 ng/ml) at 48 h, 1.0 ng/ml (0.1-2.7 ng/ml) at five days, and to 0.7 ng/ml (0.5-1.3 ng/ml) on day seven.
Individual and mean serum concentrations of K 1 in the two supplemented groups, expressed on a logarithmic scale, are shown in Fig. 1 These elevated levels fell by at least 50% within 48 h in two of the four patients given oral MM K 1 , in both of the patients given i.v. MM K 1 , and in none of the three in the placebo group (Fig. 2) . In the two patients from the oral group whose serum PIVKA-II levels rose further after vitamin K, the maximum incremental K 1 rise of 2.3 ng/ml indicated poor intestinal absorption in both.
Two other patients had markedly raised PIVKA-II levels (> 10 AU/ml and 8 AU/ml), which were in the same range as that found in patients with overt vitamin K deficiency or during oral anticoagulation therapy. One of these patients was given i.v.
K 1 , and the PIVKA-II level fell from > 10 AU/ml to 3.3 AU/ml after 48 h (and to 0.50 AU/ml on day 7), with a corresponding fall improvement in the INR from 2.2 to 1.0.
The other patient was in the placebo group, and the PIVKA-II level rose from 8 AU/ml to > 10 AU/ml at all subsequent time points between 24 h and 7 days.
Following an initial fall improvement in the INR from 2.6 at admission to 1.3 at 48 h, the INR again increased to 2.6 on day 7 despite improving liver function tests, and subsequently returned to normal 48 h after the patient was removed from the trial and given i.v. MM K 1 . King's College Hospital. At admission, 10 (20%) had K 1 levels above the upper limit of the non-fasting range (1.6 ng/ml). PIVKA-II has a long terminal half-life and may remain detectable in plasma for several days after correction of vitamin K deficiency.
To the authors' knowledge, this is the first detailed study of vitamin K status in severe acute liver dysfunction and the first placebo-controlled study of vitamin K prophylaxis using either the intravenous or oral route. Under normal physiological conditions, 40-70% of an oral dose of K 1 is absorbed from the jejunum and ileum of the upper intestine and as for other fat-soluble vitamins and highly lipid-soluble nutrients, the intraluminal phase of absorption involves the solubilisation of K 1 into mixed micelles 77 . In the present study, we found that only 20% of patients given the oral MM formulation developed an incremental serum K 1 rise ≥ 10 ng/ml at 24 h, compared with all but one (94%) of those given i.v. K 1 .
In the patients in whom serum half-lives could be estimated, the mean K 1 terminal half-life of 25.3 ± 3.7 h was about approximaely twofold longer than that found in subjects with normal hepatic function given pharmacological doses of the same MM preparation 2738 . This finding of a prolonged terminal half-life in patients with severe acute liver dysfunction is not unexpected, since tracer experiments with labelled phylloquinone in normal individuals have shown that a sizable fraction of a single dose is rapidly catabolised in the liver, with at least 40-50% excreted in the faeces via the bile and 20% excreted in the urine within three days 77 .
In summary, over a quarter of our patients presenting with severe acute liver damage had evidence of subclinical K 1 deficiency at admission, which was corrected by a single dose of i.v. MM K 1 . Intestinal absorption of MM K 1 in these patients was unreliable, so that there is no rationale to change our current practice of recommending i.v. K 1 to patients with severe liver disease and an associated coagulopathy. Based on the findings of a markedly prolonged serum K 1 half-life in these patients, a single dose of 10 mg K 1 given i.v. appears to be sufficient to maintain supraphysiological vitamin K blood levels for at least a week.
